---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-039898"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2026-08-24T21:13:36+00:00"
generated_at: "2026-08-24T21:14:23.174496+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ensyce raises $21M initial tranche of $43M Series C financing; Nasdaq compliance update

## Summary
- Initial closing Aug 7, 2026 raised >$21M gross; issued 120,260 Series C preferred shares.
- Two-tranche $43M Securities Purchase Agreement; second tranche closes on clinical milestone.
- Company believes it satisfies Nasdaq's $2.5M minimum stockholders' equity (Rule 5550(b)(1)).
- Requested Aug 24, 2026 for second 180-day grace period on $1.00 bid price rule (equity >=$5M).

## SEC filing metadata
- accession: 0001493152-26-039898
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2026-08-24T21:13:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315226039898/0001493152-26-039898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315226039898/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-039898
- JSON: https://secwatch.observer/filing/0001493152-26-039898.json
- Plain text: https://secwatch.observer/filing/0001493152-26-039898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.